AI Meets Psychedelics: Red Light Holland Taps Autonomous AI to Accelerate Clinical Trials

TORONTO, ON – March 18, 2026 – In a move that signals a significant convergence of artificial intelligence and psychedelic medicine, Red Light Holland Corp. announced it will deploy an advanced AI platform to accelerate the clinical development of a promising botanical psilocybin drug candidate. The company has engaged Kala Bio’s Researgency.ai platform to support the strategic advancement of PEX010, a patented psilocybin compound originated by Filament Health.

The partnership comes on the heels of Red Light Holland’s definitive agreement to acquire Filament Health, a deal that brings one of the largest intellectual property portfolios in botanical psychedelics under its roof. By integrating purpose-built AI agents into its newly expanded drug development pipeline, Red Light Holland is betting that algorithms can help solve some of the most time-consuming and costly challenges in bringing a novel therapeutic to market.

This collaboration aims to leverage autonomous AI to optimize clinical trial planning, simulate study scenarios, and refine research protocols for PEX010, which is already being studied in over 70 clinical sites worldwide for conditions ranging from depression to substance use disorders. The move reflects a broader industry trend where biotech and pharmaceutical giants are turning to specialized AI to gain a competitive edge in the complex world of drug discovery.

The Agentic AI Catalyst

At the heart of the collaboration is Researgency.ai, an “agentic AI” platform developed by Younet.ai and licensed exclusively to Kala Bio for the life sciences industry. Unlike conventional AI tools that assist with specific tasks, agentic AI is designed to perform goal-driven reasoning. These autonomous agents can set objectives, plan actions, gather evidence, and adapt their approach without constant human supervision, effectively creating automated research loops.

“As we move to integrate Filament’s exceptional clinical assets and intellectual property, engaging Kala Bio’s Researgency.ai platform is a natural next step in building a best-in-class psychedelic drug development operation,” said Todd Shapiro, CEO of Red Light Holland, in a statement. “By applying autonomous AI-driven research capabilities to our clinical development planning, we believe we can accelerate timelines, strengthen study designs, and make smarter, faster decisions.”

A key feature of the platform is its on-premises deployment model, which ensures that sensitive and proprietary biological data remains secure within a company’s own infrastructure. This addresses major data sovereignty and security concerns, a critical factor for companies developing valuable intellectual property in the pharmaceutical space.

Kala Bio’s platform is designed to deploy specific agents for high-value tasks, such as a Clinical Trial Agent that can draft study protocols and prepare documentation, or a Regulatory Agent that helps ensure submissions to bodies like the FDA are complete and correctly formatted. For Red Light Holland, this could mean compressing research timelines that typically take weeks or months into a fraction of the time, potentially saving millions of dollars and accelerating the path to regulatory submission.

PEX010: A Botanical Contender on the Digital Fast Track

The focus of this new AI-driven effort is PEX010, Filament Health’s lead drug candidate. As a botanical psilocybin, it is derived from a natural source rather than synthesized in a lab—a key differentiator in a market dominated by synthetic compounds. The drug is protected by a portion of Filament’s 76 issued patents and has already achieved significant milestones.

PEX010 has received authorization from both Health Canada and the U.S. Food and Drug Administration (FDA) for clinical trials and has demonstrated positive Phase 2 data for treating alcohol use disorder. It is currently under investigation at world-renowned institutions like Johns Hopkins University and the Dana-Farber Cancer Institute for a host of conditions, including treatment-resistant depression, methamphetamine use disorder, and cancer-related anxiety.

“Filament’s focus from the beginning has been to build a strong scientific and intellectual property foundation for botanical psilocybin drug development,” noted Ben Lightburn, CEO of Filament Health. He added that applying advanced analytical tools like Researgency.ai has the potential to strengthen how clinical strategies are evaluated as the program evolves.
The challenge with a drug like PEX010, which is being studied across multiple indications simultaneously, is the sheer complexity of managing and optimizing its development. The AI platform is expected to analyze vast datasets to identify patterns, predict outcomes, and model different trial designs, allowing the research team to select the most efficient and promising paths forward.

Navigating the Dual Frontiers of AI and Psychedelic Regulation

The partnership operates at the intersection of two of the most heavily scrutinized frontiers in healthcare: psychedelic medicine and artificial intelligence. Regulators like the FDA and Health Canada have shown cautious optimism toward both, but demand rigorous validation.

The FDA has granted “Breakthrough Therapy” designation for psilocybin in depression, acknowledging its potential and expediting its review process. However, as a Schedule I substance, its path to approval is lined with stringent requirements for safety, efficacy, and manufacturing consistency. Simultaneously, the agency is developing frameworks for the use of AI in drug development, emphasizing the need for transparency, validation, and what it calls “Good Machine Learning Practice.”

By using a sophisticated AI platform to design and justify its clinical trials, Red Light Holland may be able to present regulators with a more robust, data-driven case for PEX010. The ability to simulate thousands of scenarios and provide a clear rationale for every aspect of a trial’s design could prove to be a powerful advantage in navigating this complex regulatory landscape.

“Psychedelic drug development is a complex, rapidly evolving field where the ability to quickly simulate and evaluate clinical scenarios can make a meaningful difference,” said Avi Minkowitz, CEO of Kala Bio. “We are excited to work with the Red Light team as they advance one of the leading botanical psilocybin programs in the world.”

This strategic adoption of AI mirrors moves by major pharmaceutical players like Eli Lilly and technology giants such as NVIDIA, which have committed significant resources to integrating AI into drug R&D. For the burgeoning psychedelic industry, which is moving from a phase of initial hype to one of serious consolidation and scientific rigor, this partnership marks a pivotal moment. It represents a deliberate strategy to leverage cutting-edge technology to not only accelerate scientific discovery but also build a defensible and efficient business model in the future of medicine.